Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Thyroid Nodule Test Could Reduce Unnecessary Surgeries

By HospiMedica staff writers
Posted on 29 May 2008
By testing suspicious thyroid nodules using fine needle aspiration (FNA) for the presence of galectin-3--a lectin molecule that binds specific sugars--a substantial number of unnecessary surgical procedures could be eliminated, claims a new study. More...


Researchers at Sant'Andrea Hospital (Rome, Italy) performed an Italian national study in 465 subjects who had thyroid nodules larger than 1 cm in diameter for which malignancy could not be determined. The subjects enrolled between Jun 1, 2003 and August 30, 2006, were mostly women aged 21 to 76 years, with an average age of 50. The nodules were removed and analyzed with histological testing to determine whether they were cancerous or not. These results were compared to the results of galectin-3 tests.

The results showed that in 71% of the nodules, galectin-3 was not expressed. Of these galectin-3 negative nodules, 85% of them were, as predicted, benign, but 9% were cancerous and thus indicated potential false negatives. Of these, 28% showed different galectin-3 expression when tested post-operatively, suggesting that the false result could have been caused by technical problems in the test. The total sensitivity of the test was 78%, and specificity was 93%. The positive predictive value was 82% and the negative predictive value was 91%. The study was published in the May 19, 2008, issue of The Lancet Oncology.

"The galectin-3 method proposed here does not replace conventional FNA cytology, but represents a complementary diagnostic method for those follicular nodules that remain indeterminate. The correct approach for this preoperative characterization of thyroid nodules always needs careful multidisciplinary assessment of each patient, according to published guidelines,” concluded lead author Armando Bartolazzi, M.D., Ph.D., and colleagues of the department of pathology.

Galectin-3, (Gal-3), a member of the beta-galactoside binding lectin family, is an anti-apoptotic protein that protects T cells, macrophages, and breast carcinoma cells from death triggered by a variety of agents. It is not normally found in the cytoplasm of healthy thyroid cells; if it is abnormally present, it can block cell death, leading to the eventual development of cancer.


Related Links:
Sant'Andrea Hospital

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.